7月2日，赛默飞世尔盘中上涨3.01%，报528.775美元/股，成交额2.91亿美元。
消息面上，Arcturus Therapeutics宣布与赛默飞世尔达成战略合作，授予后者对其囊性纤维化候选药物ARCT-032的独家商业化生产权利。根据协议，赛默飞世尔将利用旗下Accelerator药物开发解决方案及PPD临床研究业务，支持该疗法从二期临床推进至潜在商业化阶段。此次合作进一步拓展了赛默飞世尔在生物制药服务领域的布局，与公司此前完成88.75亿美元收购Clario、启用旗舰级生物工艺设计中心等战略举措一脉相承，持续强化其端到端制药服务能力。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.